Table 2 Summary results of five initial Lung-MAP sub-studies [17]
From: Umbrella and basket trials in oncology: ethical challenges
Sub-study | ClinicalTrials.gov identifier | Final accrual | Response rate to investigational therapy N (%) | Comment |
|---|---|---|---|---|
S1400A (non-match) | NCT02766335 | Total: 116 | 11 (16) | Administratively closed to enable activation of a new non-match study |
Chemotherapy: 38 | ||||
MEDI4736: 78 | ||||
S1400B | NCT02785913 | Total: 39 | 1 (4) | Failed to meet its primary endpoint,closed at interim futility analysis |
Chemotherapy: 8 | ||||
GDC-0032: 31 | ||||
S1400C | NCT02785939 | Total: 54 | 2 (6) | Failed to meet its primary endpoint,closed at interim futility analysis |
Chemotherapy: 17 | ||||
Palbociclib: 37 | ||||
S1400D | NCT02965378 | Total: 45 | 2 (7) | Failed to meet its primary endpoint, closed at interim futility analysis |
Chemotherapy: 10 | ||||
AZD4547: 35 | ||||
S1400E | NCT02926638 | Total: 9 | N/A | Closed early due to discontinuation of development of rilotumumab |
Erlotinib: 5 | ||||
Erlotinib + Rilotumumab: 4 |